Paying users zone. Data is hidden behind: .
Get 1-month access to Merck & Co. Inc. for $19.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Merck & Co. Inc. pages available today for free:
Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Merck & Co. Inc., solvency ratios (quarterly data)
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Merck & Co. Inc.’s debt to equity ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Merck & Co. Inc.’s debt to capital ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Merck & Co. Inc.’s debt to assets ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Merck & Co. Inc.’s financial leverage ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
Debt to Equity
Merck & Co. Inc., debt to equity calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Loans payable and current portion of long-term debt | ||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | ||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to equity1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09).
1 Q4 2020 Calculation
Debt to equity = Total debt ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Merck & Co. Inc.’s debt to equity ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Debt to Capital
Merck & Co. Inc., debt to capital calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Loans payable and current portion of long-term debt | ||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | ||||||||||||||||||||||||||
Total capital | ||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to capital1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09).
1 Q4 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Merck & Co. Inc.’s debt to capital ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Debt to Assets
Merck & Co. Inc., debt to assets calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Loans payable and current portion of long-term debt | ||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to assets1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09).
1 Q4 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Merck & Co. Inc.’s debt to assets ratio improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Financial Leverage
Merck & Co. Inc., financial leverage calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | ||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||
Financial leverage1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Illumina Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09).
1 Q4 2020 Calculation
Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Merck & Co. Inc.’s financial leverage ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |